Oral ondansetron for the control of delayed emesis after cisplatin: Report of a phase II study and a review of completed trials to manage delayed emesis

M. G. Kris, L. B. Tyson, R. A. Clark, Richard J. Gralla

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background. Despite excellent control of vomiting during the initial 24 hours after chemotherapy with combination antiemetics, most patients who receive cisplatin at doses of 120 mg/m2 experience delayed emesis 24-120 hours after chemotherapy. Methods. Twenty patients receiving cisplatin (≥ 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5- HT3) antagonist, in controlling delayed emesis. All patients received intravenous metoclopramide, dexamethasone, and lorazepam for the control of acute emesis 0-24 hours after receiving cisplatin. They then received ondansetron 16 mg orally three times a day for 4 days. Results. Fifteen percent of those who were treated with oral ondansetron had complete control of delayed emesis during the entire 4-day period (95% confidence interval, 3- 38%). No serious adverse events occurred. Conclusions. At the dose and schedule tested, oral ondansetron did not appear to control delayed emesis. Previous trials of programs to lessen this complication suggest that both metoclopramide and dexamethasone are effective in lessening delayed vomiting and that the combination of these drugs is more effective than placebo. Although in one trial ondansetron appeared to control delayed emesis in patients who received cisplatin at doses of 50-120 mg/m2, it was not superior to either placebo or metoclopramide in two randomized studies. Additional testing of the 5-HT3 antagonists, both alone and in combination, will be needed to establish their role in the management of this condition.

Original languageEnglish (US)
Pages (from-to)1012-1016
Number of pages5
JournalCancer
Volume70
Issue number4 SUPPL.
StatePublished - 1992
Externally publishedYes

Fingerprint

Ondansetron
Cisplatin
Vomiting
Metoclopramide
Serotonin 5-HT3 Receptor Antagonists
Dexamethasone
Placebos
Lorazepam
Drug Therapy
Antiemetics
Drug Combinations
Combination Drug Therapy
Appointments and Schedules
Confidence Intervals

Keywords

  • cisplatin
  • delayed emesis
  • ondansetron
  • serotonin
  • vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral ondansetron for the control of delayed emesis after cisplatin : Report of a phase II study and a review of completed trials to manage delayed emesis. / Kris, M. G.; Tyson, L. B.; Clark, R. A.; Gralla, Richard J.

In: Cancer, Vol. 70, No. 4 SUPPL., 1992, p. 1012-1016.

Research output: Contribution to journalArticle

Kris, M. G. ; Tyson, L. B. ; Clark, R. A. ; Gralla, Richard J. / Oral ondansetron for the control of delayed emesis after cisplatin : Report of a phase II study and a review of completed trials to manage delayed emesis. In: Cancer. 1992 ; Vol. 70, No. 4 SUPPL. pp. 1012-1016.
@article{fdf858149c454f92a936b0fd4023db80,
title = "Oral ondansetron for the control of delayed emesis after cisplatin: Report of a phase II study and a review of completed trials to manage delayed emesis",
abstract = "Background. Despite excellent control of vomiting during the initial 24 hours after chemotherapy with combination antiemetics, most patients who receive cisplatin at doses of 120 mg/m2 experience delayed emesis 24-120 hours after chemotherapy. Methods. Twenty patients receiving cisplatin (≥ 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5- HT3) antagonist, in controlling delayed emesis. All patients received intravenous metoclopramide, dexamethasone, and lorazepam for the control of acute emesis 0-24 hours after receiving cisplatin. They then received ondansetron 16 mg orally three times a day for 4 days. Results. Fifteen percent of those who were treated with oral ondansetron had complete control of delayed emesis during the entire 4-day period (95{\%} confidence interval, 3- 38{\%}). No serious adverse events occurred. Conclusions. At the dose and schedule tested, oral ondansetron did not appear to control delayed emesis. Previous trials of programs to lessen this complication suggest that both metoclopramide and dexamethasone are effective in lessening delayed vomiting and that the combination of these drugs is more effective than placebo. Although in one trial ondansetron appeared to control delayed emesis in patients who received cisplatin at doses of 50-120 mg/m2, it was not superior to either placebo or metoclopramide in two randomized studies. Additional testing of the 5-HT3 antagonists, both alone and in combination, will be needed to establish their role in the management of this condition.",
keywords = "cisplatin, delayed emesis, ondansetron, serotonin, vomiting",
author = "Kris, {M. G.} and Tyson, {L. B.} and Clark, {R. A.} and Gralla, {Richard J.}",
year = "1992",
language = "English (US)",
volume = "70",
pages = "1012--1016",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Oral ondansetron for the control of delayed emesis after cisplatin

T2 - Report of a phase II study and a review of completed trials to manage delayed emesis

AU - Kris, M. G.

AU - Tyson, L. B.

AU - Clark, R. A.

AU - Gralla, Richard J.

PY - 1992

Y1 - 1992

N2 - Background. Despite excellent control of vomiting during the initial 24 hours after chemotherapy with combination antiemetics, most patients who receive cisplatin at doses of 120 mg/m2 experience delayed emesis 24-120 hours after chemotherapy. Methods. Twenty patients receiving cisplatin (≥ 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5- HT3) antagonist, in controlling delayed emesis. All patients received intravenous metoclopramide, dexamethasone, and lorazepam for the control of acute emesis 0-24 hours after receiving cisplatin. They then received ondansetron 16 mg orally three times a day for 4 days. Results. Fifteen percent of those who were treated with oral ondansetron had complete control of delayed emesis during the entire 4-day period (95% confidence interval, 3- 38%). No serious adverse events occurred. Conclusions. At the dose and schedule tested, oral ondansetron did not appear to control delayed emesis. Previous trials of programs to lessen this complication suggest that both metoclopramide and dexamethasone are effective in lessening delayed vomiting and that the combination of these drugs is more effective than placebo. Although in one trial ondansetron appeared to control delayed emesis in patients who received cisplatin at doses of 50-120 mg/m2, it was not superior to either placebo or metoclopramide in two randomized studies. Additional testing of the 5-HT3 antagonists, both alone and in combination, will be needed to establish their role in the management of this condition.

AB - Background. Despite excellent control of vomiting during the initial 24 hours after chemotherapy with combination antiemetics, most patients who receive cisplatin at doses of 120 mg/m2 experience delayed emesis 24-120 hours after chemotherapy. Methods. Twenty patients receiving cisplatin (≥ 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5- HT3) antagonist, in controlling delayed emesis. All patients received intravenous metoclopramide, dexamethasone, and lorazepam for the control of acute emesis 0-24 hours after receiving cisplatin. They then received ondansetron 16 mg orally three times a day for 4 days. Results. Fifteen percent of those who were treated with oral ondansetron had complete control of delayed emesis during the entire 4-day period (95% confidence interval, 3- 38%). No serious adverse events occurred. Conclusions. At the dose and schedule tested, oral ondansetron did not appear to control delayed emesis. Previous trials of programs to lessen this complication suggest that both metoclopramide and dexamethasone are effective in lessening delayed vomiting and that the combination of these drugs is more effective than placebo. Although in one trial ondansetron appeared to control delayed emesis in patients who received cisplatin at doses of 50-120 mg/m2, it was not superior to either placebo or metoclopramide in two randomized studies. Additional testing of the 5-HT3 antagonists, both alone and in combination, will be needed to establish their role in the management of this condition.

KW - cisplatin

KW - delayed emesis

KW - ondansetron

KW - serotonin

KW - vomiting

UR - http://www.scopus.com/inward/record.url?scp=0026708065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026708065&partnerID=8YFLogxK

M3 - Article

C2 - 1386282

AN - SCOPUS:0026708065

VL - 70

SP - 1012

EP - 1016

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4 SUPPL.

ER -